Program
ML-007C
A development code. Also written as “ML-007C-MA”, “ML-007C-MA BID” and “ML-007C-MA QD”.
Its studies are mostly in Alzheimer Disease · Schizophrenia, led by MapLight Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MapLight Therapeutics | 43 open or running | phase 2since Mar 14, 2025 | Mar 14, 2025 | Dec 2027phase 2 · NCT06887192 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2025First study: phase 2 study in Alzheimer DiseaseFirst studyNCT06887192 · 300 planned · United States, Argentina, Bulgaria and more
- Jun 18, 2025Phase 2 study in SchizophreniaNCT07038876 · 307 enrolled · United States
- Mar 5, 20262 phase 2 studiesNCT07459660, NCT07459647
Ahead
- Dec 2027Primary completion: phase 2 study in Alzheimer DiseaseNCT06887192
- Mar 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07459660
- Feb 2030Primary completion: phase 2 study in SchizophreniaNCT07459647
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459660Alzheimer Disease · United States, Bulgaria, France | 2 | By invitation | Mar 2029 | 210 |
| NCT07459647Schizophrenia · United States | 2 | Recruiting | Feb 2030 | 500 |
| NCT07038876Schizophrenia · United States | 2 | Completed | Jun 4, 2026 | 307 |
| NCT06887192Alzheimer Disease · United States, Argentina, Bulgaria and more | 2 | Recruiting | Dec 2027 | 300 |
How it is read
Names in the registry
- “ML-007C-MA”, 3 entries
- “ML-007C-MA BID”, 1 entry
- “ML-007C-MA QD”, 1 entry
Codes read as this program: ML007C.
Conditions, from the studies’ own filings
- Alzheimer Disease, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.